A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma

Status Not yet recruiting

Clinical Trial Summary

This is a single-center, open, single-arm, phase II clinical study to investigate the efficacy and safety of patients with soft tissue sarcoma who have failed anthracycline-containing chemotherapy and whose antivascular agents have been effective and failed. Progression-free survival (PFS) was used as the primary outcome measure to preliminatively estimate the efficacy and safety of 29 patients with soft tissue sarcoma who had failed chemotherapy with anthracyclines and who had received effective and failed antivascular agents. Sofantinib 300mg orally, once a day, with continuous administration every 21 days, until the disease progresses or becomes intolerable; Imaging methods were used every 6 weeks (±7 days) after enrollment according to RECIST1.1 standard to evaluate the efficacy of tumor.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06110650
Study type	Interventional
Source	Fudan University
Contact	Xiaowei zhang
Phone	15921521116
Email	dongfangzhizizhxw@aliyun.com
Status	Not yet recruiting
Phase	N/A
Start date	November 28, 2023
Completion date	August 15, 2025

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04577014` - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma	Phase 1/Phase 2
Recruiting	`NCT04656262` - Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients	Phase 3
Recruiting	`NCT03077178` - Impact of Locoregional Treatment of Soft Tissue Sarcoma on Status of Patients Aged 70 Years and Over	N/A
Terminated	`NCT03735758` - Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib	Phase 4
Not yet recruiting	`NCT03951571` - Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma	Phase 2
Enrolling by invitation	`NCT03134742` - Radiation Effects on Bone
Not yet recruiting	`NCT06252727` - Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES)	Phase 1
Recruiting	`NCT04617327` - Pre-operative RadiothErapy for Soft Tissue SarcOmas	N/A
Recruiting	`NCT06385288` - Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcomas	N/A
Recruiting	`NCT05116254` - Sarcomas and DDR-Inhibition; a Combined Modality Study	Phase 1
Active, not recruiting	`NCT03526679` - Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma	Phase 1/Phase 2
Recruiting	`NCT04008238` - Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients	N/A
Recruiting	`NCT04095208` - Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study	Phase 2
Recruiting	`NCT04330456` - Combined Treatment of Patients With Soft Tissue Sarcoma Including Preoperative Stereotactic Radiation Therapy and Postoperative Conformal Radiation Therapy	N/A
Completed	`NCT03833037` - Study of a Cohort of Cases of Synovial Sarcoma Treated in the Orthopedic Surgery and Traumatology Department of the Hospital de Sant Pau Between 1983 and 2016
Completed	`NCT03056599` - Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma	Phase 1
Recruiting	`NCT05961761` - Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients	Phase 2
Recruiting	`NCT06273852` - A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors	Early Phase 1
Recruiting	`NCT05182164` - Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas	Phase 2
Withdrawn	`NCT03104335` - Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial	Phase 2